Overview

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.
Phase:
Phase 3
Details
Lead Sponsor:
Albireo